Medtronic (NYSE:MDT) announced on Tuesday that the U.S. FDA cleared its SmartGuard algorithm as an interoperable automated glycemic controller, allowing the integration of its MiniMed 780G insulin ...
The MarketWatch News Department was not involved in the creation of this content. NORTHRIDGE, Calif., March 10, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed), a global leader in full stack ...
GALWAY, Ireland, Dec. 2, 2025 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the broad U.S. commercial launch of the MiniMed™ 780G system integrated ...
Medtronic has earned FDA approval that will allow it to broaden the scope of its MiniMed 780G system portfolio. FDA has cleared Medtronic’s SmartGuard algorithm as an interoperable automated glycemic ...
Add Yahoo as a preferred source to see more of our stories on Google. Medtronic has received 510(k) clearance for the use of its MiniMed 780G pump with two ultra-rapid-acting insulins and with a ...
GALWAY, Ireland, Sept. 2, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced two U.S. Food and Drug Administration (FDA) regulatory milestones ...
NORTHRIDGE, Calif., March 10, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed), a global leader in full stack insulin delivery, today announced CE (Conformité Européenne) Mark for use of the ...
Medtronic plc MDT has begun the broad U.S. commercial rollout of the MiniMed 780G system integrated with Abbott’s ABT Instinct sensor, designed exclusively for MiniMed systems. Earlier this year, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results